LEVULAN KERASTICK Rx
Generic Name and Formulations:
Aminolevulinic acid HCl 20%; topical soln; contains alcohol.
Sun Pharmaceutical Industries
Indications for LEVULAN KERASTICK:
In combination with blue light illumination (BLU-U Blue Light Photodynamic Therapy Illuminator), for the treatment of minimally to moderately thick actinic keratoses of the face, scalp, or upper extremities.
Clean and dry affected area. Apply to lesions on either scalp, face, or upper extremities, but not simultaneously. One application and one dose of illumination per treatment site per 8-week treatment session. Face or scalp: illumination (second stage) must take place 14–18hrs after application. Protect treated lesions from sun with a head covering. Upper extremities: occlude treated lesions with low density polyethylene plastic wrap and net dressing; protect from sun with long-sleeved shirt and/or gloves. Illumination (second stage) must take place 3hrs after application. Delay in illumination: protect treated lesions for ≥40hrs; see full labeling. Treated lesions not completely resolved after 8 weeks may be treated a second time.
<18yrs: not established.
Cutaneous photosensitivity at wavelengths of 400–450nm. Porphyria or known allergies to porphyrins.
Avoid exposure of photosensitive treatment sites to sunlight or bright indoor light for ≥40hrs. Avoid applying to eyes, mucous membranes, perilesional skin (no more than 5mm around target lesions). Excessive irritation if applied under occlusion >3hrs. Inherited or acquired coagulation defects. Pregnancy. Nursing mothers.
Increased photosensitivity reaction with concomitant photosensitizing agents (eg, griseofulvin, thiazides, sulfonylureas, phenothiazines, sulfonamides, tetracyclines, St. John's wort).
Local reactions (eg, stinging/burning, erythema, edema, scaling/crusting, itching, erosion, hypo-/hyperpigmentation, oozing/vesiculation, dryness); photosensitivity, transient amnestic episodes (monitor).
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline